

Jury Awards Groundskeeper $289.2 Million in Landmark Monsanto Roundup Verdict
Mounting evidence suggests that exposure to Monsanto’s Roundup weed killer increases the risk of developing non-Hodgkin lymphoma, a blood cancer that starts in cells called lymphocytes, which are part of the body’s immune system.
Monsanto’s Roundup weed killer accounted for roughly $994 million in net sales between fiscal years 2013 and 2014. While farmers account for the majority of Roundup sales, many Americans with a garden to tend likely have a small bottle of Roundup on hand to kill weeds.
The meteoric rise in Roundup’s popularity mirrors that of Monsanto’s own timeline—the agrochemical giant began selling herbicides in the mid-20th century, and then developed genetically modified seeds that are resistant to the effects of non-selective herbicides. Both inventions made it easy for farmers to spray Roundup indiscriminately on large tracts of land, killing weeds without affecting their crops.
The problem is that Monsanto marketed Roundup as being a safe product for decades, even though the company allegedly knew that a Roundup cancer link existed, along with a host of other serious health issues. A number of Roundup cancer studies have confirmed that glyphosate exposure is a probable cause of non-Hodgkin lymphoma and other cancers.
Glyphosate, the active ingredient in the Monsanto Roundup weed killer and other companies’ products, has been listed as a probable cause of non-Hodgkin lymphoma by the International Agency for Research on Cancer (IARC), which is the World Health Organization’s cancer research arm.
The 2015 IARC glyphosate classification was based on a review of multiple studies on the effects of glyphosate on agricultural and forestry workers since 2001. The evidence shows that people who were exposed to glyphosate experienced higher reported incidences of non-Hodgkin lymphoma than those who weren’t exposed to the herbicide. The IARC report further points out that glyphosate is currently used in 750 products around the world, and use of the herbicide has “increased sharply with the development of genetically modified glyphosate-resistant crop varieties.”
Over the last 30 years, there has been an increase in reported cases of non-Hodgkin lymphoma, according to a major scientific review published in 2014. The study suggests that chemical pesticides and herbicides—particularly glyphosate, the active ingredient in Roundup weed killer—are a major contributing factor to the rising number of non-Hodgkin lymphoma cases.
The Roundup cancer study, titled “Non-Hodgkin Lymphoma and Occupational Exposure to Agricultural Pesticide Chemical Groups and Active Ingredients: A Systematic Review and Meta-Analysis, was published in the International Journal of Environmental Research and Public Health. The paper focused on reviews and meta-analyses of nearly 30 years worth of epidemiological research examining the link between non-Hodgkin lymphoma and occupational exposure to 80 pesticide active ingredients and 21 chemical groups. The study notes that pesticides are often grouped according to the type of pests that they control; for example, fungicides are used to kill fungi, insecticides to kill insects, and herbicides to kill weeds and plants.
The 2014 glyphosate cancer study attempted to reconcile an apparent trend among farm workers who have low mortality rates but high reported incidents of cancer. Researchers believe that exposure to Roundup may best explain this contradiction, as the Roundup cancer study found that being exposed to glyphosate doubled an individual’s risk of developing non-Hodgkin lymphoma.
Aside from demonstrating that pesticide exposure in occupational agricultural settings is an important determinant of non-Hodgkin lymphoma, the study also found that glyphosate exposure was linked to a common non-Hodgkin lymphoma subtype, B-cell lymphoma.
Non-Hodgkin lymphoma symptoms can vary widely in accordance with where it is in the body. In certain circumstances, the cancer may not have any indicators until it grows large. According to the American Cancer Society, the following are the most common signs and symptoms of non-Hodgkin’s lymphoma in different parts of the body:
You should also be aware of the following general non-Hodgkin’s lymphoma symptoms:
When lymphoma cells are in the bone marrow, they can overrun the healthy cells that form new blood cells. This crowding out of healthy blood cells can cause:
Many of the non-Hodgkin’s lymphoma symptoms listed above can be related to other issues or diseases that aren’t cancer. However, if you have been using a glyphosate herbicide, such as Monsanto’s Roundup weed killer, it is important to go see a health care professional as soon as possible if any of these symptoms should develop in order to get a proper diagnosis.
The World Health Organization’s International Agency for Research on Cancer (IARC) has found a statistically significant positive association between glyphosate exposure and non-Hodgkin’s lymphoma.
Contact our team at Wisner Baum today to schedule a consultation.
"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.
The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
$289.2 million jury verdict in Monsanto Roundup trial
Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.
Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.
Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.